证券日报网讯 12月4日，新华医疗在互动平台回答投资者提问时表示，公司整体运营稳健，坚持高质量 发展，具体财务数据以公司定期报告披露为准。 （文章来源：证券日报） ...

证券日报网讯 12月4日，新华医疗在互动平台回答投资者提问时表示，公司聚力提升企业高质量发展能 力和核心竞争力，保持业绩稳定增长。具体财务数据以公司定期报告披露为准。 （文章来源：证券日报） ...

（编辑 丛可心 袁冠琳） 证券日报网讯 12月4日，新华医疗在互动平台回答投资者提问时表示，公司聚焦医疗器械、制药装备两 大主业，其中放疗及影像设备、高端制药装备等核心产品技术水平达到世界一流水准，业务范畴契合高 端装备制造业中高端医疗装备、智能制造装备的产业定位，是国家重点高新技术企业及国家制造业单项 冠军企业，深度参与高端装备制造领域的技术创新与产业发展。公司在2024年11月实现了医美行业首单 突破，首套面膜冻干生产线顺利通过客户验收并交付，该设备在技术上实现了多项创新，大幅提升了生 产效率。 ...

Core Viewpoint - Xinhua Medical stated that Huajian Medical is an important associate company, and the company's investment income will be affected by the changes in Huajian Medical's net profit [2] Group 1 - Xinhua Medical uses the equity method to account for its investment in Huajian Medical [2] - Changes in Huajian Medical's net profit will impact Xinhua Medical's investment returns [2]

证券日报网讯 12月4日，新华医疗在互动平台回答投资者提问时表示，公司2025年度主要指标预算为国 际营业收入与2024年度相比增长不低于30%。 （文章来源：证券日报） ...

证券日报网讯 12月4日，新华医疗在互动平台回答投资者提问时表示，公司严格按照证券监管的相关规 定进行信息披露，公司重视市值管理，正积极通过控股股东增持、优化分红、完善治理结构、实施股权 激励等方式方法进行市值管理。 （文章来源：证券日报） ...

证券日报网讯12月4日，新华医疗（600587）在互动平台回答投资者提问时表示，公司已发布减持公 告，自新华医疗董事会决议之日起12个月内，华佗国际通过公开市场交易方式减持华检医疗不超过5% 股份。 ...

Group 1 - The core viewpoint of the article is that Xinhua Medical is considering stock repurchase and cancellation based on various factors including future business plans and financial conditions [1] - The company will strictly adhere to information disclosure rules if there are any related arrangements in the future [1]

Core Viewpoint - The stock of Xinhua Medical (600587) has shown a slight increase, with a closing price of 15.04 yuan on December 4, 2025, reflecting a 0.33% rise, while the company faces declining revenue and profit trends in its recent financial performance [1][3]. Financial Performance - For the first three quarters of 2025, Xinhua Medical reported a main business revenue of 6.978 billion yuan, a year-on-year decrease of 6.0% [3]. - The net profit attributable to shareholders was 434 million yuan, down 29.61% year-on-year, while the net profit after deducting non-recurring gains and losses was 370 million yuan, a decline of 38.98% [3]. - In Q3 2025, the company recorded a single-quarter main business revenue of 2.188 billion yuan, a decrease of 2.2% year-on-year, and a net profit of approximately 48.59 million yuan, down 63.39% year-on-year [3]. Market Position and Ratios - Xinhua Medical's total market value is 9.124 billion yuan, which is below the industry average of 10.958 billion yuan, ranking 40th out of 124 in the medical device industry [3]. - The company has a price-to-earnings ratio (P/E) of 15.76, significantly lower than the industry average of 60.57, ranking 5th in the industry [3]. - The gross profit margin stands at 25.11%, which is considerably lower than the industry average of 51.22%, ranking 111th out of 124 [3]. Investment Sentiment - In the last 90 days, two institutions have given a rating of "buy" for Xinhua Medical, with an average target price of 20.0 yuan [4].

Core Viewpoint - The company is progressing with the development of its lower limb exoskeleton robot, which is currently in the prototype stage and is expected to complete product development by 2026 and obtain medical device registration by 2027 [1]. Group 1 - The company has received a notice of acceptance for its patent application from the National Intellectual Property Administration for the lower limb assistive exoskeleton robot, which is set to undergo clinical trials [1]. - The product is designed for multiple application scenarios, including hospitals, communities, homes, and elderly care institutions [1]. - The expected timeline for the completion of product development is 2026, with medical device registration anticipated in 2027 [1].